Hypoglycemia in patients with type 2 diabetes treated with oral antihyperglycemic agents detected by continuous glucose monitoring: a multi-center prospective observational study in Croatia

Maja Baretić, Valeria Bralić Lang, Maja Baretić, Valeria Bralić Lang

Abstract

Background: Hypoglycemia in type 2 diabetes mellitus (T2DM) is still unsolved issue. The aim of this study was to investigate hypoglycemia in T2DM in participants treated with oral antihyperglycemic agents using different glucose cut-off values and to explore influence of different therapies.

Methods: This multi-center prospective observational study included participant with T2DM from primary care offices across Croatia treated with antihyperglycemic agents who were monitored using professional continuous glucose monitoring (CGM) device (iPro™2). Hypoglycemia was defined as at least 1% of the monitored period spent in the hypoglycemic range and/or area under the curve of glycemia registered ever under the defined cut-off value. The higher upper limit of blood glucose cut-off value was 3.9 mmol/L (70 mg/dL) and the lower one 3.0 mmol/L (54 mg/dL).

Results: Study included 94 participants. Median hemoglobin A1C levels, age, T2DM duration, body mass index, and CGM use duration were 7 (5.8-11.5) %, 65 (40-86) years, 7 (1-36) years, 30.4 (21.3-41.5) kg/m2 and 6 (1-7) days, respectively. Fifty participants were treated with sulfonylurea, primarily gliclazide (84%). The percentage of participant with hypoglycemia based on the higher cut-off value was 42.6% vs. 16% based on the higher cut-off value. The percentage of participant with nocturnal hypoglycemia (23 PM to 06 AM) was significantly lower among participant with hypoglycemia based on the higher cut-off value compared to lower one (7.8% vs. 22.9%). Sulfonylurea treatment did not influence the occurrence of hypoglycemia. Analysis of the data from participants having hypoglycemia based on the lower cut-off value pointed to other possible risk factors for hypoglycemia like prolonged overnight fasting, physical activity, alcohol consumption, and concomitant therapy with angiotensin-converting enzyme inhibitors.

Conclusions: In participant with T2DM treated with oral antihyperglycemic agents hypoglycemia based on the blood glucose cut-off value of 3.9 mmol/L was more prevalent, but with less nocturnal hypoglycemia. Sulfonylurea therapy was not risk factor for hypoglycemia regardless of cut-off value. In participants having hypoglycemia based on the blood glucose cut-off value of 3.0 mmol/L some other possible factors were identified related to concomitant therapy, nutrition and daily habits.

Trial registration: ClinicalTrials.gov Identifier: NCT03253237.

Keywords: Continuous glucose monitoring; Hypoglycemia; Oral antihyperglycemic agents; Type 2 diabetes.

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40:1631–1640. doi: 10.2337/dc17-1600.
    1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (JDRF-CGM) trial. Diabetes Care. 2010;33:17–22. doi: 10.2337/dc09-1502.
    1. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2019 executive summary. Endocr Pract. 2019;25:69–100. doi: 10.4158/CS-2018-0535.
    1. Pazos-Couselo M, García-López JM, González-Rodríguez M, Gude F, Mayán-Santos JM, Rodríguez-Segade S, et al. High incidence of hypoglycemia in stable insulin-treated type 2 diabetes mellitus: continuous glucose monitoring vs. self-monitored blood glucose. Observational prospective study. Can J Diabetes. 2015;39:428–433. doi: 10.1016/j.jcjd.2015.05.007.
    1. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005;28:2948–2961. doi: 10.2337/diacare.28.12.2948.
    1. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care. 1989;12:203–207. doi: 10.2337/diacare.12.3.203.
    1. Miller CD, Philips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi M. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001;161:1653–1659. doi: 10.1001/archinte.161.13.1653.
    1. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylurea. Arch Intern Med. 1997;157:1681–1686. doi: 10.1001/archinte.1997.00440360095010.
    1. Khunti K, Alsifri S, Aronson R, Cigrovski Berković M, Enters-Weijnen C, Forsén T, et al. HAT Investigator Group. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18:907–915. doi: 10.1111/dom.12689.
    1. Lipska KJ, Warton EM, Huang ES, Moffet HH, Inzucchi SE, Krumholz HM, et al. HbA1c and risk of severe hypoglycemia in type 2 diabetes: the diabetes and aging study. Diabetes Care. 2013;36:3535–3542. doi: 10.2337/dc13-0610.
    1. Zick R, Petersen B, Richter M, Haug C, SAFIR Study Group Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with type 2 diabetes on multiple daily insulin injection therapy. Diabetes Technol Ther. 2007;9:483–492. doi: 10.1089/dia.2007.0230.
    1. Klimontov VV, Myakina NE. Glucose variability indices predict the episodes of nocturnal hypoglycemia in elderly type 2 diabetic patients treated with insulin. Diabetes Metab Syndr. 2017;11:119–124. doi: 10.1016/j.dsx.2016.08.023.
    1. International Hypoglycaemia Study Group Minimizing hypoglycemia in diabetes. Diabetes Care. 2015;38:1583–1591. doi: 10.2337/dc15-0279.
    1. Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH. Hypoglycemia in type 2 diabetes - more common than you think: a continuous glucose monitoring study. J Diabetes Sci Technol. 2015;9:999–1005. doi: 10.1177/1932296815581052.
    1. Goff DC, Jr, Gerstein HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, et al. Prevention of cardiovascular diseas in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:4i–20i. doi: 10.1016/j.amjcard.2007.03.002.
    1. Juvenilne Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Fox LA, Beck RW, Xing D. Variation of interstitial glucose measurements assessed by continuous glucose monitors in healthy, nondiabetic individuals. Diabetes Care. 2010;33:1297–1299. doi: 10.2337/dc09-1971.
    1. Zhou J, Li H, Ran X, Yang W, Li Q, Peng Y, et al. Reference values for continuous glucose monitoring in Chinese subjects. Diabetes Care. 2009;32:1188–1193. doi: 10.2337/dc09-0076.
    1. Andersen SE, Christensen M. Hypoglycaemia when adding sulphonylurea to metformin: a systematic reviewand network meta-analysis. BrJ Clin Pharmacol. 2016;82:1291–1302. doi: 10.1111/bcp.13059.
    1. Van Dalen J, Brouvers MCGJ, Stehouwer CDA, Krings A, Leufkens HGM, Driessen JHM, et al. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relationto renal function and sulphonylurea metabolite group:population based cohort study. British Med J. 2016;354:i3625.
    1. van Dijk P, Bouma A, Landman GW, Groenier KH, Bilo H, Kleefstra N, et al. Hypoglycemia in frail elderly patients with type 2 diabetes mellitus treated with sulfonylurea. J Diabetes Sci Technol. 2017;11:438–439. doi: 10.1177/1932296816668873.
    1. Mbanya JC, Al-Sifri S, Abdel-Rahim A, Satman I. Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: a meta-analytical approach. Diabetes Res Clin Pract. 2015;109:226–232. doi: 10.1016/j.diabres.2015.04.030.
    1. Turner BC, Jenkins E, Kerr D, Sherwin RS, Cavan DA. The effect of evening alcohol consumption on next-morning glucose control in type 1 diabetes. Diabetes Care. 2001;24:1888–1893. doi: 10.2337/diacare.24.11.1888.
    1. Herings RM, de Boer A, Stricker BH, Leufkens HG, Porsius A. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet. 1995;345:1195–1198. doi: 10.1016/S0140-6736(95)91988-0.
    1. Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care. 2010;33:147–167. doi: 10.2337/dc10-9990.
    1. Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther. 2011;13:921–928. doi: 10.1089/dia.2010.0247.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa